AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06658964
Drug: Cohort 2: JMKX003142 and rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.~Rifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD
Trial: NCT06660940
Drug: Keluoxin Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment period (52 weeks):Keluoxin Capsules, 4 capsules/time, swallow with warm water after meals, 3 times/day
Trial: NCT06660940
Drug: Keluoxin Capsule Simulants
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment period (52 weeks):Keluoxin Capsule Simulants, 4 capsules/time, swallow with warm water after meals, 3 times/day
Trial: NCT05033639
Drug: Melatonin 6 MG
RxNorm normalized name: melatonin 6 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin is an endogenously produced indolamine principally synthesized in the pineal gland from serotonin. It is described as a ubiquitous molecule which plays a vital role in the physiologic function of the body. Melatonin, also known as N-acetyl-5-methoxytryptamine which has a a) immunomodulator; b) free radical scavenger; c) prevention of oxidative stress and d) anti-inflammatory7-10.
Trial: NCT06660017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm will receive unmedicated syrup solution dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
Trial: NCT04707768
Drug: Mircera®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration
Trial: NCT05362773
Drug: MGD024
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.
Trial: NCT06658626
Drug: [¹⁴C]Enlicitide chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Injection
Trial: NCT06752668
Drug: ORX750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORX750 capsule.
Trial: NCT06752668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORX750 matching placebo capsule.
Trial: NCT05319730
Drug: Acetaminophen (or equivalent)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered per product label.
Trial: NCT05319730
Drug: Supportive care measures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
Trial: NCT06690242
Drug: MT1013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT1013 is a novel calcimimetic agent
Trial: NCT06690242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The measure does not contain the active ingredients
Trial: NCT06717815
Drug: IPG11406
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Medical Products:~IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed.
Trial: NCT06749457
Drug: AZD7760
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive AZD7760 as a single intravenous infusion.
Trial: NCT05417594
Drug: AZD9574
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive AZD9574 orally.
Trial: NCT05417594
Drug: [11C]AZ1419 3391
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive \[11C\]AZ1419 3391 intravenously.
Trial: NCT06659341
Drug: BAY3498264
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04734418
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pump injection.The initial dose of remifentanil is 0.05 μg/kg/min.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of remifentanil is 0.12 μg/kg/min
Trial: NCT06375304
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention consists of prescribing B/F/TAF to eligible ART-experienced migrant patients, free of charge, in four care settings, for 12 months (48 weeks).~B/F/TAF is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements.
Trial: NCT05711615
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05711615
Drug: Peposertib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06362226
Drug: Steroid/Antibiotic (Maxitrol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group one subjects receive topical maxitrol ophthalmic ointment twice daily for two weeks
Trial: NCT06362226
Drug: 5-FU/Kenalog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group two undergoes treatment with a subcutaneous injection of a 5-fluorouracil (5-FU) and Kenalog (triamcinolone) combination (80/20 ratio, 0.3-0.5 mL per session) administered in four sessions, spaced two weeks apart, starting within 48 hours of hospital presentation
Trial: NCT05098574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appearance, packaging, and labeling of placebo will be matched to their active counterpart.
Trial: NCT05422365
Drug: Intravenous immunoglobulin (IVIG), 10% solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
Trial: NCT04433741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously
Trial: NCT05750056
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received a perioperative saline infusion at the same rate and volume as the lidocaine infusion.
Trial: NCT05750056
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentail 0.1 ug/kg was administered for sedation induction.
Trial: NCT05898672
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral dose of rosuvastatin tablets
Trial: NCT05129280
Drug: RO7444973
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7444973 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective cohort.
Trial: NCT06313502
Drug: 75gm HDAA
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 75gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 120 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded.
Trial: NCT06313502
Drug: 125gm HDAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 125gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 240 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded.
Trial: NCT05479097
Drug: Anti-Hypertensive
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on information entered by the CHWs into the CommCare application designed for this study, the application will provide recommendations (and underlying rationale for these recommendations) for prescription of antihypertensives (amlodipine and/or losartan OR enalapril) and medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated, lifestyle modification, and referral to the supervising physician if indicated for potential complications of hypertension.
Trial: NCT06067100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are administered placebo
Trial: NCT06017609
Drug: Placebo Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching in appearance to the active drug capsules
Trial: NCT04202406
Drug: Acetaminophen and codeine and caffeine
RxNorm normalized name: acetaminophen / caffeine / codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive pretreatment oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine 1 hour before treatment.
Trial: NCT04202406
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive pretreatment oral single dose of 1000mg acetaminophen alone 1 hour before treatment.
Trial: NCT04202406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive placebo (starch) 1hour before treatment.
Trial: NCT06605651
Drug: 0.9% NaCl solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three intra-articular injections during and/or following DAIR procedure
Trial: NCT06658054
Drug: Adjuvant analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive adjuvant dexmedetomidine (25mcg) and dexamethasone (5mg) in addition to bupivacaine.
Trial: NCT06660329
Drug: Janus Kinase Inhibitor
RxNorm normalized name: Janus kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib is used according to weight: 5\~\<7kg，2mg；7\~\<10kg，2.5mg；10\~\<15kg，3mg；15\~\<25kg，3.5mg；25\~\<40kg，4mg；≥40kg，5mg. All is twice a day.
Trial: NCT06661018
Drug: Coenzyme Q 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participant will receive STEMI standard treatment plus oral Coenzyme Q10 (chewable tablet) 100 mg / 12 hours for 8 weeks
Trial: NCT06661018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participant will receive STEMI standard treatment plus placebo /12 hours for 8 weeks
Trial: NCT06608238
Drug: D-MNA 200 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-MNA , (doxorubicin) patch, 200 mcg
Trial: NCT06608238
Drug: D-MNA 100 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-MNA (doxorubicin) patch, 100 mcg
Trial: NCT04726592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV
Trial: NCT04726592
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg IV
Trial: NCT06660784
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depending on the indication, the subjects will be given NO treatment or not. In ECMO assisted mechanical ventilation + NO treatment group, the subjects will be randomly assigned to NO treatment via ventilator or membrane oxygenator.
Trial: NCT06660992
Drug: HSK31858, tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis
Trial: NCT06660992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo comparator of study
Trial: NCT06657859
Drug: GLM101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLM101 IV infusion
Trial: NCT05422534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo or CoQ10/day for 12 weeks
Trial: NCT05858853
Drug: Recombinant Human Serum Albumin
RxNorm normalized name: RECOMBINANT HUMAN SERUM ALBUMIN ORYZA SATIVA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days
Trial: NCT05858853
Drug: Recombinant Human Serum Albumin
RxNorm normalized name: RECOMBINANT HUMAN SERUM ALBUMIN ORYZA SATIVA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
Trial: NCT05049213
Drug: Carrageenan nasal spray and 1% PVP- mouthwash and gargle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day1 to Day7~1. Intranasal spray 3 times/day, 2\~3 spray/nostril/per time~2. Oral gargling 3 times/day, 15cc/per time
Trial: NCT04673942
Drug: Checkpoint Inhibitor, Immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
Trial: NCT05609877
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline will be administered intravenously instead of pre-procedure analgesia.
Trial: NCT05609877
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 0.5-1.0 mcg/kg will be administered intravenously as pre-procedure analgesia
Trial: NCT06481371
Drug: zuojinwan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the Chinese medicine combination group, 3g of Zuojinwan was added to the western medicine group twice a day for 4 weeks.
Trial: NCT05058612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose PO/NG 18h
Trial: NCT05148442
Drug: IBI322
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant anti-human CD47/PD-L1 bispecific antibody
Trial: NCT04554966
Drug: Placebo for ABBV-382
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT05825430
Drug: general anaesthetic technique only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
Trial: NCT05069714
Drug: MTX-hold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary discontinuation of methotrexate for 1 or 2 weeks
Trial: NCT05191888
Drug: Vonoprazan, Amoxicillin and Clarithromycin
RxNorm normalized name: vonoprazan, amoxicillin and clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day vonoprazan triple therapy
Trial: NCT05191888
Drug: Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14th Rabeprazole reverse mixed therapy
Trial: NCT05220319
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional 100ml will be given.
Trial: NCT04727632
Drug: [18F]Fluoroestradiol (FES) PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]Fluoroestradiol (FES) PET/CT
Trial: NCT06405737
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects assigned to receive intranasal administration of placebo (24 IU).
Trial: NCT05803161
Drug: Congrong Runtong oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Congrong Runtong oral liquid：component total glycosides of Cistanche extracted and refined from the traditional Chinese medicine Cistanche deserticola
Trial: NCT05803161
Drug: Placental Congrong Runtong oral liquid
RxNorm normalized name: human placental tissue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placental Congrong Runtong oral liquid
Trial: NCT04971239
Drug: topical methotrexate micoemulsion
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
Trial: NCT05295784
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
Trial: NCT05397041
Drug: BMB-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one of several different oral doses of BMB-101 once or twice daily
Trial: NCT05397041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo
Trial: NCT06341296
Drug: LV
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg/m\^2, d1, 14 days per cycle, 8 cycles.
Trial: NCT05727800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for oral administration.
Trial: NCT04710550
Drug: F18-3F4AP
RxNorm normalized name: fluorodeoxyglucose F18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET Scan
Trial: NCT04975919
Drug: Decitabine and Cedazuridine
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04738357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05099055
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 100 mcg of morphine, 15 mcg of fentanyl and 0.25 ml of normal salin (sterile) with 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
Trial: NCT04748757
Drug: recombinant human annexin A5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant human annexin A5, manufactured as SY-005
Trial: NCT04748757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 50 ml
Trial: NCT05025098
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1. During Cycle 1 Days 1 - 3, the dose of Venetoclax will ramp up from 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Azacitidine (100 mg/m2) is given once daily following administration of venetoclax for 5 days of every cycle, starting on Day 1 of each cycle.~For MDS patients: Azacitidine (100 mg/m2) is given once daily for 5 days of every 28 day cycle, starting on day 1 of each cycle.
Trial: NCT05025098
Drug: Precision therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision therapy for both AML and MDS patients is standard therapy + tumor board determined precision therapy. The tumor board determined precision therapy can be all available drugs with a marketing authorization in Norway.
Trial: NCT06581731
Drug: remimazolam combined with remifentanil
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in this group will receive a bolus of remimazolam 5 mg intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 mg/kg/h remimazolam via separate syringe pumps.
Trial: NCT06581731
Drug: dexmedetomidine combined with remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive a loading dose of dexmedetomidine 1 μg/kg over 10 minutes intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 μg/kg/h dexmedetomidine via separate syringe pumps.
Trial: NCT06398730
Drug: GEH200520 Injection and GEH200521 (18F) Injection
RxNorm normalized name: INFLAMMATION AND INFECTION DETECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of GEH200520 Injection followed by GEH200521 (18F) Injection
Trial: NCT05447195
Drug: CAN008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given CAN008 + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the CAN008+TMZ maintenance therapy period in which subjects in both groups are given CAN008+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given CAN008 IV infusion weekly until disease progression.